Chemical Technology

Employee Scheduling for Manufacturing: A Best Practices Guide

June 16, 2021

As demand continues to surge for many chemical manufacturers, ensuring adequate staffing to meet daily volume targets is a top-of-mind issue for plant managers. Read the guide to discover the best practices of employee scheduling you can leverage to improve the overall effectiveness of labor resources

Spotlight

Cara Therapeutics

Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat pain, inflammation and pruritus. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's most advanced patented compound, CR845, is currently undergoing clinical testing for acute pain and uremic pruritus. This compound possesses analgesic, anti-inflammatory and antipruritic activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.

OTHER WHITEPAPERS
news image

Electrochemical Destruction of Perfluorooctanesulfonatein Electroplating Wastewaters

whitePaper | August 15, 2022

Experiments were conducted to investigate 6:2 FTS oxidation, as this is a common replacement compound for PFOS in the electroplating industry.

Read More
news image

Industrial Internet of Things for hazardous areas: potential for the optimisation of existing plants

whitePaper | February 11, 2020

Whether oil and gas, chemicals, pharmaceuticals, mining or food, the development of an Industrial Internet of Things (IIoT) in combination with algorithms and artificial intelligence, releases an enormous optimisation potential - also and especially for existing plants. New business models transform CAPEX into OPEX and reduce the financial risk. For this, however, the information chain consisting of individual IIoT modules must not only be stringent,

Read More
news image

Planet Positive Chemicals

whitePaper | September 24, 2022

Climate action in the global chemical industry is lagging compared to other sectors. As of August 2022, only seventeen industry players had committed to targets in line with a 1.5 degrees future as part of the Science Based Targets initiative (SBTi).

Read More
news image

Chemical Engineering Essentials for the CPL Professional

whitePaper | January 9, 2023

For more than 120 years, Chemical Engineering has been the leading source for news, technology and analysis used by engineers, operators, plant managers, senior managers and consultants worldwide.

Read More
news image

PLASTIC FOR PROFIT

whitePaper | July 12, 2021

The author wishes to thank Willie Wilson for his advice and support with stakeholder mapping throughout the project, Linh Tran Phuong Dang for helping with research and data collection, and many individuals and organizations that have shared their knowledge, including INTERPOL’s Pollution Crime Working Group; the environmental agencies of the United Kingdom, Zambia, Ghana and South Africa; the Environment and Natural Resources Division at the United States Department of Justice;

Read More
news image

Validation of Titration Methods

whitePaper | September 8, 2022

The quality of your product depends on the analyses performed in quality control. That is why you rely on first-rate analytical instruments for the most accurate and precise results, and product quality

Read More

Spotlight

Cara Therapeutics

Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat pain, inflammation and pruritus. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's most advanced patented compound, CR845, is currently undergoing clinical testing for acute pain and uremic pruritus. This compound possesses analgesic, anti-inflammatory and antipruritic activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.

Events